1. Analytical Agreement and Clinical Correlates of Plasma Brain Natriuretic Peptide Measured by Three Immunoassays in Patients with Heart Failure
- Author
-
Tarcisio Vago, Guido Norbiato, Serge Masson, G. Baldi, Maurizio Bevilacqua, and Roberto Latini
- Subjects
chemistry.chemical_classification ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Biochemistry (medical) ,Clinical Biochemistry ,Peptide ,medicine.disease ,Brain natriuretic peptide ,Endocrinology ,Atrial natriuretic peptide ,chemistry ,Heart failure ,Immunoassay ,Cardiac hypertrophy ,Internal medicine ,cardiovascular system ,medicine ,Cardiology ,In patient ,cardiovascular diseases ,Myocardial infarction ,business ,hormones, hormone substitutes, and hormone antagonists - Abstract
Brain natriuretic peptide (BNP) is a 32-amino acid peptide structurally related to atrial natriuretic peptide and predominantly secreted by myocardial ventricles. Interest in this peptide has recently increased because its concentration carries prognostic value in patients with myocardial infarction [1] , congestive heart failure (CHF) [2] , or cardiac hypertrophy [3] . The circulating concentration of BNP is also a predictor of mortality, independently of cardiovascular disease [4] . Three commercially available immunoassay methods are designed to measure the plasma concentration of human BNP: two recent nonextraction assays and an older extraction RIA. Here, we compared these three immunoassays and correlated them …
- Published
- 1997
- Full Text
- View/download PDF